BUZZ-IntelliPharmaCeutics International Inc: FDA imposes new conditions
** Generic drug maker's shares down 7 pct at $3.19
** FDA indicated that IntelliPharmaCeutics' generic Attention Deficit Hyperactivity Disorder treatment will have to meet new conditions to prove it is as effective as existing therapy, company says
** Says FDA decision affects 4 out of 6 doses, which have only conditional approval
** Says will pursue "all reasonable courses of action" to get final approval, along with its U.S. marketing partner Par Pharmaceutical Inc
** Up to Thursday's close, stock had risen nealry 53 pct this year
© Thomson Reuters 2017 All rights reserved.